
    
      There are two stages to this study: a dose-escalation stage and a dose-expansion stage.

      Dose-escalation stage: hmpl-309 administered orally once every day(QD) to patients with
      locally advanced or metastatic solid tumors for whom standard therapy either does not exist
      or has proven to be ineffective or intolerable. Dose-expansion stage: hmpl-309 administered
      orally 300mg once every day(QD) to patients which is only for patients with EGFR positive
      oesophageal carcinoma.
    
  